Hypertension and Cardiovascular Risk Factors

Valsartan Plus Hydrochlorothiazide in Patients With Hypertension and Cardiovascular Risk Factors

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00171782

Enrollment

Registered

2005-09-15

Start date

2004-02-29

Completion date

2004-12-31

Last updated

2023-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HYPERTENSION

Keywords

HYPERTENSION, VALSARTAN, VALSARTAN AND HYDROCHLOROTHIAZIDE, RISK FACTORS

Brief summary

A study to evaluate the efficacy of valsartan+chydochlorothiazide in patients with stage 2 hypertension and cardiovascular risk factors.

Interventions

DRUGVALSARTAN+HYDROCHLOROTHIAZIDE

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Inclusion criteria

* \- Patients who give consent * Men and women 18 to 80 years of age * Patients with hypertension (systolic \>159 mm, diastolic \>100 mm) * Patients meeting laboratory criteria

Exclusion criteria

* \- Pregnant women * Women not using approved contraception methods * Secondary hypertension Other protocol-defined

Design outcomes

Primary

Measure	Time frame
Change from baseline systolic blood pressure at 8 weeks	—

Secondary

Measure	Time frame
Blood pressure less than 140/90 mmHg at 8 weeks	—
Reduction from baseline in diastolic blood pressure greater than or equal to 10 mmHg	—
Reduction from baseline in systolic blood pressure greater than or equal to 20 mmHg	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026